Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Biomarker expression and treatment response following neoadjuvant chemotherapy in western gastric cancer
EF 2018-19
Résumé
Stomach cancer is one of the most common cancers worldwide and the third leading cause of cancer related death. Stomach cancer is treated with a combination of surgery and medicine such as chemotherapy. Despite treatment, patients often pass away from cancer spread or from cancer returning after treatment.
Using laboratory tests certain molecules have been found to be involved in the growth and spread of stomach cancer. Much in the way that every individual has a unique signature to identify themselves, stomach cancers also have a signature of molecules that may differ from one to the other. Some cancers may be more aggressive than others and are less responsive to chemotherapy treatment whereas other cancers diminish significantly by the exact same treatment. We believe that each cancer’s unique signature of molecules may be related to treatment effectiveness. Furthermore, we plan to identify new effective drugs for stomach cancer based on their ability to attack certain molecules.
In our study, western Canadian human gastric cancer samples will be tested in the laboratory for a variety of molecules. We will then correlate these molecules to the severity of cancer and a variety of chemotherapy drugs will be administered to the cancer cells in order to determine if certain molecules can predict treatment response.
We hope to connect each unique stomach cancer’s molecular signature to the effectiveness of different chemotherapy treatments in order to one day provide personalized medicine. For example one patient’s cancer may respond to one drug whereas another patient’s cancer responds to another. If we can predict which drugs will be most beneficial then we can provide better treatment, potentially with fewer medications and less side effects.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406335
Name
Skubleny Daniel T
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Biomarker expression and treatment response following neoadjuvant chemotherapy in western gastric cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarker; Canada; Cancer; Chemotherapy; Gastric; Molecular; Personalized
Abstract
Stomach cancer is one of the most common cancers worldwide and the third leading cause of cancer related death. Stomach cancer is treated with a combination of surgery and medicine such as chemotherapy. Despite treatment, patients often pass away from cancer spread or from cancer returning after treatment.
Using laboratory tests certain molecules have been found to be involved in the growth and spread of stomach cancer. Much in the way that every individual has a unique signature to identify themselves, stomach cancers also have a signature of molecules that may differ from one to the other. Some cancers may be more aggressive than others and are less responsive to chemotherapy treatment whereas other cancers diminish significantly by the exact same treatment. We believe that each cancer’s unique signature of molecules may be related to treatment effectiveness. Furthermore, we plan to identify new effective drugs for stomach cancer based on their ability to attack certain molecules.
In our study, western Canadian human gastric cancer samples will be tested in the laboratory for a variety of molecules. We will then correlate these molecules to the severity of cancer and a variety of chemotherapy drugs will be administered to the cancer cells in order to determine if certain molecules can predict treatment response.
We hope to connect each unique stomach cancer’s molecular signature to the effectiveness of different chemotherapy treatments in order to one day provide personalized medicine. For example one patient’s cancer may respond to one drug whereas another patient’s cancer responds to another. If we can predict which drugs will be most beneficial then we can provide better treatment, potentially with fewer medications and less side effects.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Skubleny, Daniel T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~